SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(van de Giessen E) ;lar1:(gu)"

Sökning: WFRF:(van de Giessen E) > Göteborgs universitet

  • Resultat 1-3 av 3
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Visser, D., et al. (författare)
  • Tau pathology as determinant of changes in atrophy and cerebral blood flow: a multi-modal longitudinal imaging study
  • 2023
  • Ingår i: European Journal of Nuclear Medicine and Molecular Imaging. - : Springer Science and Business Media LLC. - 1619-7070 .- 1619-7089. ; 50:8, s. 2409-19
  • Tidskriftsartikel (refereegranskat)abstract
    • PurposeTau pathology is associated with concurrent atrophy and decreased cerebral blood flow (CBF) in Alzheimer's disease (AD), but less is known about their temporal relationships. Our aim was therefore to investigate the association of concurrent and longitudinal tau PET with longitudinal changes in atrophy and relative CBF.MethodsWe included 61 individuals from the Amsterdam Dementia Cohort (mean age 65.1 +/- 7.5 years, 44% female, 57% amyloid-beta positive [A beta +], 26 cognitively impaired [CI]) who underwent dynamic [F-18]flortaucipir PET and structural MRI at baseline and 25 +/- 5 months follow-up. In addition, we included 86 individuals (68 CI) who only underwent baseline dynamic [F-18]flortaucipir PET and MRI scans to increase power in our statistical models. We obtained [F-18]flortaucipir PET binding potential (BPND) and R-1 values reflecting tau load and relative CBF, respectively, and computed cortical thickness from the structural MRI scans using FreeSurfer. We assessed the regional associations between i) baseline and ii) annual change in tau PET BPND in Braak I, III/IV, and V/VI regions and cortical thickness or R-1 in cortical gray matter regions (spanning the whole brain) over time using linear mixed models with random intercepts adjusted for age, sex, time between baseline and follow-up assessments, and baseline BPND in case of analyses with annual change as determinant. All analyses were performed in A beta- cognitively normal (CN) individuals and A beta+ (CN and CI) individuals separately.ResultsIn A beta+ individuals, greater baseline Braak III/IV and V/VI tau PET binding was associated with faster cortical thinning in primarily frontotemporal regions. Annual changes in tau PET were not associated with cortical thinning over time in either A beta+ or A beta- individuals. Baseline tau PET was not associated with longitudinal changes in relative CBF, but increases in Braak III/IV tau PET over time were associated with increases in parietal relative CBF over time in A beta + individuals.ConclusionWe showed that higher tau load was related to accelerated cortical thinning, but not to decreases in relative CBF. Moreover, tau PET load at baseline was a stronger predictor of cortical thinning than change of tau PET signal.
  •  
2.
  • Chetelat, G., et al. (författare)
  • Amyloid-PET and 18-F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias
  • 2020
  • Ingår i: Lancet Neurology. - 1474-4422 .- 1474-4465. ; 19:11, s. 951-962
  • Forskningsöversikt (refereegranskat)abstract
    • Various biomarkers are available to support the diagnosis of neurodegenerative diseases in clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET, which assesses brain amyloid deposition, and F-18-fluorodeoxyglucose (F-18-FDG) PET, which assesses glucose metabolism, provide valuable and complementary information. However, uncertainty remains regarding the optimal timepoint, combination, and an order in which these PET biomarkers should be used in diagnostic evaluations because conclusive evidence is missing. Following an expert panel discussion, we reached an agreement on the specific use of the individual biomarkers, based on available evidence and clinical expertise. We propose a diagnostic algorithm with optimal timepoints for these PET biomarkers, also taking into account evidence from other biomarkers, for early and differential diagnosis of neurodegenerative diseases that can lead to dementia. We propose three main diagnostic pathways with distinct biomarker sequences, in which amyloid-PET and F-18-FDG-PET are placed at different positions in the order of diagnostic evaluations, depending on clinical presentation. We hope that this algorithm can support diagnostic decision making in specialist clinical settings with access to these biomarkers and might stimulate further research towards optimal diagnostic strategies.
  •  
3.
  • Mathies, Franziska L., et al. (författare)
  • The Early Perfusion Image Is Useful to Support the Visual Interpretation of Brain Amyloid-PET With 18F-Flutemetamol in Borderline Cases
  • 2024
  • Ingår i: CLINICAL NUCLEAR MEDICINE. - 0363-9762 .- 1536-0229. ; 49:9, s. 838-846
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose: Visual interpretation of brain amyloid-beta (A beta) PET can be difficult in individuals with borderline A beta burden. Coregistration with individual MRI is recommended in these cases, which, however, is not always available. This study evaluated coregistration with the early perfusion frames acquired immediately after tracer injection to support the visual interpretation of the late A beta-frames in PET with F-18-flutemetamol (FMM). Patients and Methods: Fifty dual-time-window FMM-PET scans of cognitively normal subjects with 0 to 60 Centiloids were included retrospectively (70.1 +/- 6.9 years, 56% female, MMSE score 28.9 +/- 1.3, 42% APOE epsilon 4 carrier). Regional A beta load was scored with respect to a 6-point Likert scale by 3 independent raters in the 10 regions of interest recommended for FMM reading using 3 different settings: A beta image only, A beta image coregistered with MRI, and A beta image coregistered with the perfusion image. The impact of setting, within- and between-readers variability, region of interest, and A beta-status was tested by repeated-measure analysis of variance of the Likert score. Results: The Centiloid scale ranged between 2 and 52 (interquartile range, 7-19). Support of visual scoring by the perfusion image resulted in the best discrimination between A beta-positive and A beta-negative cases, mainly by improved certainty of excluding A beta plaques in A beta-negative cases (P = 0.030). It also resulted in significantly higher between-rater agreement. The setting effect was most pronounced in the frontal lobe and in the posterior cingulate cortex/precuneus area (P = 0.005). Conclusions: The early perfusion image is a suitable alternative to T1-weighted MRI to support the visual interpretation of the late A beta image in FMM-PET.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-3 av 3

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy